Skip to main content
Premium Trial:

Request an Annual Quote

Nanogen Licenses Schizophrenia Biomarkers From Aussie Groups

NEW YORK (GenomeWeb News) — Nanogen has licensed genetic markers related to schizophrenia and to antipsychotic drug response from Australia’s Co-Operative Research Centre for Diagnostics and Queensland University of Technology.
Nanogen said it will use the markers to develop diagnostics for schizophrenia and “related conditions,” and said that some of the markers may be useful in predicting adverse drug reactions. The company said these markers have been linked to the disease “in a number of clinical studies.”
Financial terms of the agreement were not released.
Nanogen President and COO David Ludvigson said that effective schizophrenia diagnostics and treatments may “require multiplexed analytic methods capable of examining multiple genes simultaneously” because the disease may be caused by mutations in multiple genes.
The genetic component of schizophrenia may account for between 65 percent and 80 percent of the risk for the disease.

The Scan

Boosters Chasing Variants

The New York Times reports that an FDA advisory panel is to weigh updated booster vaccines for COVID-19.

Not Yet

The World Health Organization says monkeypox is not yet a global emergency, the Washington Post reports.

More Proposed for Federal Research

Science reports that US House of Representatives panels are seeking to increase federal research funding.

PLOS Papers on Breast Cancer Metastasis, Left-Sided Cardiac Defects, SARS-CoV-2 Monitoring

In PLOS this week: link between breast cancer metastasis and CLIC4, sequencing analysis of left-sided cardiac defects, and more.